Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25281945 | 0.95 | HTR6 (0.38) | HTR6ACLYNPY5RGNRHRTACR1 | |
| SCHEMBL26969777 | 0.85 | HTR6 (0.40) | HTR6ACLYNPY5RGNRHRTACR1 | |
| SCHEMBL30733398 | 0.84 | ACLY (0.43) | ACLYNPY5RGNRHR | |
| SCHEMBL26969749 | 0.83 | NPY5R (0.38) | ACLYNPY5RSIGMAR1 | |
| SCHEMBL30733425 | 0.83 | CYP3A4 (0.43) | ACLYNPY5RTACR1 | |
| SCHEMBL26969732 | 0.83 | NPY5R (0.47) | NPY5RGNRHRTACR1 | |
| SCHEMBL30733427 | 0.82 | ACLY (0.42) | ACLYNPY5RGNRHR | |
| SCHEMBL26969774 | 0.82 | CYP3A4 (0.48) | ACLYNPY5RTACR1 | |
| SCHEMBL26969706 | 0.82 | SIGMAR1 (0.47) | NPY5ROPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL25237936 | 0.82 | ACLY (0.41) | ACLYNPY5RGNRHRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | HTR6 189/4885ACLY 3265/4885NPY5R 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.